Evidence map›Paper›PMID 37214919›Full record

ArticlebioRxiv : the preprint server for biology2023

Cardiomyocyte Targeting Peptide to Deliver Amiodarone.

Maliha Zahid, Beth Weber, Ray Yurko, Kazi Islam, Vaishavi Agrawal, Jack Lopuszynski, Hisato Yagi, Guy Salama

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Maliha ZahidDept. of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.
Beth WeberPittsburgh Heart, Lung, Blood, and Vascular Medicine Institute and Division of Cardiology, Department of Medicine, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Ray YurkoPeptide Synthesis Facility, University of Pittsburgh, Pittsburgh, PA.
Kazi IslamPeptide Synthesis Facility, University of Pittsburgh, Pittsburgh, PA.
Vaishavi AgrawalDietrich School of Arts and Sciences, University of Pittsburgh, Pittsburgh, PA.
Jack LopuszynskiBurnett School of Biomedical Sciences, University of Central Florida, Orlando, FL.
Hisato YagiDept. of Developmental Biology, University of Pittsburgh, Pittsburgh, PA.
Guy SalamaPittsburgh Heart, Lung, Blood, and Vascular Medicine Institute and Division of Cardiology, Department of Medicine, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
University of Pittsburgh · USUniversity of Pittsburgh Medical Center · USMayo Clinic in Arizona · USUniversity of Central Florida · US

Funding

Targeting Underlying Pathophysiological Mechanisms to Develop Novel Therapies for Chronic Obstructive Lung DiseaseR01HL153407 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZAHID, MALIHA · 2020 to 2024
$3.0M
Targeted delivery of amiodarone to the heart for atrial fibrillation utilizing novel cardiac targeting peptidesR41HL150908 · NHLBI · VIVASC THERAPEUTICS INC. · PI ZAHID, MALIHA · 2020 to 2020
$327k
NHLBI NIH HHS R01 HL153407NHLBI NIH HHS R41 HL150908
6 · The paper itself

Abstract

Background: Amiodarone is underutilized due to significant off-target toxicities. We hypothesized that targeted delivery to the heart would lead to lowering of dose by utilizing a cardiomyocyte targeting peptide (CTP), a cell penetrating peptide identified by our prior phage display work. Methods: CTP was synthesized thiolated at the N-terminus, conjugated to amiodarone via Schiff base chemistry, HPLC purified and confirmed with MALDI/TOF. Stability of the conjugate was assessed using serial HPLCs. Guinea pigs (GP) were injected intraperitoneally daily with vehicle (7 days), amiodarone (7 days; 80mg/Kg), CTP-amiodarone (5 days;26.3mg/Kg), or CTP (5 days; 17.8mg/Kg), after which GPs were euthanized, hearts excised, perfused on a Langendorff apparatus with Tyrode's solution and blebbistatin (5μM) to minimize contractions. Voltage (RH237) and Ca Results: CTP-amiodarone remained stable for up to 21 days at 37°C. At ∼1/15 Conclusions: Our data suggests that CTP can deliver amiodarone to cardiomyocytes at ∼1/15

Identifiers

PMID37214919
PMCPMC10197706
OpenAlexW4376141278

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.